Introduction/Background

Primary and Interval Debulking/Cytoreductive Surgery (PDS and IDS) are standard of care for surgical management of advanced stage 3 and 4 epithelial Ovarian/Fallopian Tubal Cancer. There has been very little research regarding outcomes of Delayed Debulking Surgery (DDS); performed upon completion of adjuvant chemotherapy. Aim to evaluate survival following DDS and compare cytoreductive outcomes, post-operative morbidity, PCI scores and survival outcomes in women who underwent PDS, IDS, DDS.

Methodology

Prospective data collection and retrospective review of all cases that underwent DDS in our centre from 1/7/2014 to 31/12/2020.

Results

All 384 patients were divided in PDS (n=109), IDS (n=235) and DDS (n=40). Mean age of the entire cohort was 64 years old. PDS and IDS group were comparable, and DDS has significantly higher comorbidities like cardiovascular and diabetes. Overall R=0 was achieved in 70% of cases with a further 12% of residual under 0.5 cm. Ongoing mean overall survival (OS) is 56 months and the complexity of surgery did not significantly impacted morbidity (mean length of hospital stay 7 days) or survival rates. There was a significant survival benefit seen with complete cytoreduction (R0) in primary, interval and delayed debulking surgery (p<0.05) and OS was not statistically different in between the three groups (p<0.05). Age over 70 years, performance status, ASA score and residual tumour volume negatively correlated to overall survival after logistic regression. On Cox regression analysis, the hazard ratio was significantly higher for R>2 cm in all sub-groups (HR=2.7, 95% CI-1.23–6.07, p<0.05).

Conclusion

Delayed debulking surgery is a safe and oncologically acceptable option for women who have missed the opportunity for clinical and/or personal reasons to undergo surgery in the primary or interval setting. We recommend that all cases that did not have surgery to be considered for surgery at completion of their chemotherapy by MDT.

Abstract 2022-RA-1675-ESGO Figure 1

Conclusion

The presence of cancer dissemination collectively in specific anatomical sites, including small bowel mesentery, diaphragmatic peritoneum, and large bowel may be more predictive of CC0 than the entire PCI and IMO. Early intra-operative assessment of these areas may reveal whether CC0 is achievable.

Abstract 2022-RA-1678-ESGO

TREATMENT PATTERNS AND OUTCOMES FOR OLDER WOMEN WITH OVARIAN CANCER IN IRELAND

1Carolyn Moloney, 2Paula Lynch, 3Ruth Kieran, 3Orla Holmes, 3Greg Karpanty, 1John Stratton, 1John McCaffrey, 1Austin Duffy, 5Paula Calvert, 1Anees Hassan, 1Roshni Kalachand. 1Medical Oncology, Mater Misericordiae University Hospital, Dublin 7, Ireland; 2Medical Oncology, Waterford University Hospital, Waterford, Ireland; 3Limerick University Hospital, Limerick, Ireland; 4Waterford University Hospital, Waterford, Ireland; 5Mater Misericordiae University Hospital, Dublin, Ireland

10.1136/ijgc-2022-ESGO.774
Abstracts

2022-RA-1683-ESGO  VTE IN NEWLY DIAGNOSED OVARIAN CANCER PATIENTS

Daniel Shai, Jacob Korach, Limor Helpman. Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel

10.1136/ijgc-2022-ESGO.775

Introduction/Background Ovarian cancer is commonly diagnosed at advanced stages, and is frequently treated with neoadjuvant chemotherapy. Advanced cancer patients are at risk for venous thromboembolism (VTE) and benefit has been shown using anticoagulants in risk stratified populations. Although a limited number of publications describe high rates of VTE among ovarian cancer patients, predictors of risk in this population have not been well studied. Our objective was to define rates of VTE among ovarian cancer patients receiving first-line chemotherapy and to identify predictors.

Methodology Ovarian cancer patients receiving first-line chemotherapy in Sheba Medical Center between 2013–2021 were identified, and data retrieved from the electronic medical record (EMR), institutional pharmacy records and imaging reports using dedicated software (MDClone©, Israel). A Natural Language Processing algorithm was created to identify VTE events to augment recorded diagnoses. Descriptive statistics were used to compare patients experiencing a VTE around and up to one year after beginning chemotherapy, to patients who did not. Logistic regression analysis was used to evaluate predictors of VTE.

Results 697 records were identified. VTE during the first year was diagnosed in 74 (10.6%), of whom 40 were DVT and 34 were PE. The majority were diagnosed in the first 6 months (figure 1). Only 5 were diagnosed in the 30-day postoperative period. Patients with a VTE diagnosis were older (mean, 65.4 vs 62.3, p=0.03) and had lower albumin levels (mean, 3.08 vs 3.29, p=0.04). Other predictors of VTE on univariable regression analysis included poor performance status, neoadjuvant chemotherapy and a Khorana Score ≥ 2, but none were found to be independent predictors (table 1).

Conclusion VTE is frequent in the first year, and particularly in the 6 months around ovarian cancer diagnosis. Risk may be predicted using established risk algorithms. Prophylactic anticoagulation may be considered in at-risk patients during first line chemotherapy.

2022-RA-1694-ESGO  A DYNAMIC, RISK-BASED DETERMINATION OF FOLLOW-UP INTERVALS FOR ADVANCED EPITHELIAL OVARIAN CANCER BASED ON SERUM CA125 TESTS

Sokbom Kang,1 Yeon Jee Lee.1 National Cancer Center, Korea, Goyang, Korea, Republic of; 2National Cancer Center, Goyang, Korea, Republic of

10.1136/ijgc-2022-ESGO.776

Introduction/Background The treatment of older women with ovarian cancer is challenging due to increased pre-existing comorbidities and frailty, often leading to less radical treatment than the standard of care. Older women are frequently excluded from clinical trials. Recent studies such as the EWOC-1 study focused on elderly women with ovarian cancer suggest worse outcomes associated with less radical treatment approaches.

Methodology Women diagnosed with ovarian cancer ≥65 years old referred to oncology services at three Irish University Hospitals between 2015 and 2021 were included. We evaluated patterns regarding surgery and chemotherapy sequencing, choice of agent and completion rates, according to age group. Survival outcomes were examined by Kaplan Meier analysis. The study received ethical approval.

Results 190 patients were included in this study. 65.26% (124) of these women had an ECOG performance status of 0–1 at diagnosis. 129 patients (67.89%) had (FIGO) stage III or stage IV disease at diagnosis. 55% of all stage III/IV patients had optimal debulking surgery. 37% of stage III/IV patients received neoadjuvant chemotherapy followed by surgery and 27% had surgery followed by chemotherapy. Women in the ≥75 group were more likely to receive single agent carboplatin (38%), compared to women aged 65–74 years (30%). Median overall survival for all stage III/IV patients who received SA Carboplatin was 15 months versus 22 months for Carboplatin and Paclitaxel groups. BRCA testing was sub-optimal in this age group at 28% of all patients who received SA Carboplatin was 15 months versus 22 months for Carboplatin and Paclitaxel groups. BRCA testing was sub-optimal in this age group at 28% of all patients although routine BRCA testing has only been available in Ireland since 2019.

Conclusion Elderly ovarian cancer patients, particularly those ≥75 years, may receive less radical treatment approaches than standard of care. Our cohort suggests improved survival with carboplatin/paclitaxel, although our cohort is too small to be definitive in standard of care. Our cohort suggests improved survival with carboplatin/paclitaxel, although our cohort is too small to be definitive in standard of care. Our cohort suggests improved survival with carboplatin/paclitaxel, although our cohort is too small to be definitive in standard of care. Our cohort suggests improved survival with carboplatin/paclitaxel, although our cohort is too small to be definitive in standard of care. Our cohort suggests improved survival with carboplatin/paclitaxel, although our cohort is too small to be definitive in standard of care.